Intra-Cellular Therapies’ CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar depression. With its differentiated safety profile ...

In a notable Genomic Press research report, researchers at the Aristotle University of Thessaloniki have uncovered a significant presence of manic symptoms in patients with schizophrenia spectrum ...

Research from Aristotle University of Thessaloniki, Greece reveals that over 26% of stable patients with schizophrenia ...

Schizophrenia is a serious mental disorder that affects around 1% of ... a neurotransmitter thought to play a central role in the pathogenesis of the disease. "A decrease in this neurotransmitter ...

Schizophrenia is a serious mental disorder that affects around 1% of ... a neurotransmitter thought to play a central role in the pathogenesis of the disease. "A decrease in this neurotransmitter ...

Caplyta is a prescription drug used to treat schizophrenia and bipolar disorder. Learn how long it takes the drug to work and how long it stays in your system.

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

THESSALONIKI, Greece, 11 February 2025 - In a notable Genomic Press research report, researchers at the Aristotle University of Thessaloniki have uncovered a significant presence of manic symptoms in ...

“We thought his behavior was odd ... Run,” which is based on her son’s journey with paranoia, bipolar disorder and schizophrenia told from her perspective. The cover shows a man running ...

Among 196 doctors who prescribed clozapine, 64% said the positive aspects of the REMS certification process outweighed the ...

Schizophrenia is perhaps the human condition,” wrote Tim Crow in 2000.1 Crow had been researching schizophrenia for most of his psychiatric career but the origins of this most complex condition had ...